OTCPK:BIEL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

BioElectronics Corporation, an electroceutical company, engages in the development and sale of wearable, neuromodulation devices to mitigate neurological diseases and enhance quality of life worldwide.


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has BioElectronics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BIEL has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

BIEL

0.8%

US Medical Equipment

0.5%

US Market


1 Year Return

-14.3%

BIEL

17.2%

US Medical Equipment

18.7%

US Market

Return vs Industry: BIEL underperformed the US Medical Equipment industry which returned 18% over the past year.

Return vs Market: BIEL underperformed the US Market which returned 20.1% over the past year.


Shareholder returns

BIELIndustryMarket
7 Day0%0.8%0.5%
30 Day-14.3%5.9%4.9%
90 Day0%14.4%19.8%
1 Year-14.3%-14.3%18.1%17.2%21.2%18.7%
3 Year0%0%76.5%71.8%46.2%36.8%
5 Year-25.0%-25.0%130.3%112.4%85.3%65.1%

Price Volatility Vs. Market

How volatile is BioElectronics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is BioElectronics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether BioElectronics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as BioElectronics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of BIEL's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through BioElectronics regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is BioElectronics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

28.7%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioElectronics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of BIEL’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on theOTC Markets Website. If you are looking for more of a qualitative research into the company, you can access BioElectronics's filings and announcementshere.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has BioElectronics performed over the past 5 years?

-25.6%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: BIEL is currently unprofitable.

Growing Profit Margin: BIEL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if BIEL's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare BIEL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BIEL is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.2%).


Return on Equity

High ROE: BIEL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is BioElectronics's financial position?


Financial Position Analysis

Short Term Liabilities: BIEL has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: BIEL has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: BIEL has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: BIEL's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if BIEL has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if BIEL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is BioElectronics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BIEL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BIEL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BIEL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BIEL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BIEL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average board tenure


CEO

Kelly Whelan

0.83

Tenure

Ms. Kelly A. Whelan serves as Executive Director at BioElectronics Corporation since November 2019. She has been Chief Executive Officer and President of BioElectronics Corporation since October 2019. She ...


Board Members

NamePositionTenureCompensationOwnership
Kelly Whelan
CEO, President0.83yrno datano data
Keith Nalepka
VP of Sales & Marketing and Executive Director0.75yrno datano data
Ian Rawe
Director of Clinical Research & Member of Medical Advisory Boardno datano datano data
Lawrence Michaelis
Chairman of Medical Advisory Boardno datano datano data
Richard Staelin
Independent Chairman0.17yrno datano data
Kenneth McLeod
Member of Medical Advisory Boardno datano datano data

0.8yrs

Average Tenure

Experienced Board: BIEL's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.1%.


Top Shareholders

Company Information

BioElectronics Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioElectronics Corporation
  • Ticker: BIEL
  • Exchange: OTCPK
  • Founded: 2000
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$14.023m
  • Shares outstanding: 23.37b
  • Website: https://www.bielcorp.com

Location

  • BioElectronics Corporation
  • 4539 Metropolitan Court
  • Frederick
  • Maryland
  • 21704
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BIELOTCPK (Pink Sheets LLC)YesCommon StockUSUSDApr 2004

Biography

BioElectronics Corporation, an electroceutical company, engages in the development and sale of wearable, neuromodulation devices to mitigate neurological diseases and enhance quality of life worldwide. Its ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/14 00:38
End of Day Share Price2020/08/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.